Biocept (BIOC) & Veracyte (VCYT) Critical Review

Biocept (NASDAQ: BIOC) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Valuation & Earnings

How to Become a New Pot Stock Millionaire

This table compares Biocept and Veracyte’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biocept $5.07 million 3.62 -$21.61 million ($0.79) -0.34
Veracyte $71.95 million 2.66 -$31.00 million ($0.91) -6.14

Biocept has higher earnings, but lower revenue than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Biocept, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biocept and Veracyte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biocept -426.48% -374.92% -169.29%
Veracyte -43.09% -68.43% -36.13%

Institutional and Insider Ownership

8.7% of Biocept shares are held by institutional investors. Comparatively, 70.5% of Veracyte shares are held by institutional investors. 7.7% of Biocept shares are held by insiders. Comparatively, 13.4% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Biocept and Veracyte, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biocept 0 0 2 0 3.00
Veracyte 0 2 3 0 2.60

Biocept currently has a consensus price target of $1.25, indicating a potential upside of 362.96%. Veracyte has a consensus price target of $11.08, indicating a potential upside of 98.21%. Given Biocept’s stronger consensus rating and higher possible upside, research analysts plainly believe Biocept is more favorable than Veracyte.

Volatility & Risk

Biocept has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Summary

Veracyte beats Biocept on 7 of the 13 factors compared between the two stocks.

Biocept Company Profile

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Veracyte Company Profile

Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional managers, account managers, and medical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

8,380 Shares in American Campus Communities  Acquired by LPL Financial LLC
8,380 Shares in American Campus Communities Acquired by LPL Financial LLC
Intrexon  Shares Sold by LPL Financial LLC
Intrexon Shares Sold by LPL Financial LLC
LPL Financial LLC Buys Shares of 7,295 Donaldson
LPL Financial LLC Buys Shares of 7,295 Donaldson
LPL Financial LLC Acquires New Stake in ProShares MSCI Europe Dividend Growers ETF
LPL Financial LLC Acquires New Stake in ProShares MSCI Europe Dividend Growers ETF
Longer Investments Inc. Has $2.55 Million Position in Microsoft Co.
Longer Investments Inc. Has $2.55 Million Position in Microsoft Co.
Apple  Shares Bought by Lenox Wealth Management Inc.
Apple Shares Bought by Lenox Wealth Management Inc.


Leave a Reply

© 2006-2018 Ticker Report. Google+.